Skip to main content

Table 2 Immunosuppressive adverse effects scoring system with central nervous system and miscellaneous adverse effects

From: Validity and reliability of a novel immunosuppressive adverse effects scoring system in renal transplant recipients

Central nervous system adverse effectsa

Tremor

 

    0:

None

    1+:

Noticeable movement of paper suspended over outstretched hands with fingers spread

    2+:

Prominent movement of suspended paper

    3+:

Resting tremor and/or tremor that impairs function

Headache

 

    0:

Absent

    1+:

Present

Insomnia

 

    0:

None

    1+:

Difficulty sleeping

    2+:

Noticeable loss of sleep; requires pharmacotherapy to achieve adequate sleep

    3+:

Severe sleep deprivation; difficulty sleeping despite pharmacotherapy

Miscellaneous adverse effects a

Myopathy

 

    0:

None

    1+:

Complaints of muscle weakness or decreased strength

    2+:

Clinically apparent weakness difficulty rising from chair or squatting position

    3+:

Muscle wasting + severe limitation of exercise capacity

Ophthalmic changes

 

    0:

No cataract formation

    1+:

Cataracts present; or surgical removal of cataracts has occurred

Mania/Excitable behavior

 

    0:

None

    1+:

Excitable behavior; rapid speech and activity level

    2+:

Very excitable behavior, actions and speech

Depression

 

    0:

None

    1+:

Depressed thoughts with normal level of activity for patient ( no antidepressants)

    2+:

Depressed thoughts with normal level of activity for patient ( with antidepressants)

    3+:

Depressed thoughts without normal level of activity for patient ( does not dress, poor hygiene, etc.) and receives anti-depressants

Post-transplant Diabetes mellitus

Symptoms of diabetes plus casual plasma glucose ≥200 mg/dl

OR

 

Fasting plasma glucose ≥126 mg/dl

OR

(two of the criteria are required)

2 hour plasma glucose ≥200 mg/dl during an oral glucose tolerance test

OR

    0: Absent

Glycated Hemoglobin A1C > 7%

OR

    1+: Present

Use of anti-diabetic agents

 

General laboratory results

Renal function – Serum Creatinine (mg/dl)

_____________________

Blood pressure

_____________________

Glucose (mg/dl)

_____________________

Glycated hemoglobin A1C (%)

_____________________

Total cholesterol (mg/dl)

_____________________

High density lipoprotein (mg/dl)

_____________________

Low density lipoprotein (mg/dl)

_____________________

Triglycerides (mg/dl)

_____________________

Total white blood cells (cell/mm3)

_____________________

Neutrophils (%)

_____________________

Lymphocytes (%)

_____________________

Platelets (cells/mm3)

_____________________

Hemoglobin (g/dl)

_____________________

Hematocrit (%)

_____________________

  1. aThe scoring system presents a quantitative severity rating of the most common adverse effects of immunosuppressive therapy. Each adverse effect was assessed as a change from pre-transplant status to document that the manifestation was attributed to immunosuppressive therapy or a change related therapy in the post-transplant period.